IUIvonne Uzair

Ivonne Uzair

*This is an algorithmically generated author record based on publicly available information.

Ivonne Uzair has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor-Intrinsic iNOS Drives Obesity-Associated Immune Suppression Through a CCL2-Dependent Myeloid Remodeling Program in Triple-Negative Breast Cancer

    by Ivonne D. Uzair, Agne Baseviciene, Jenying Deng, Recep Bayraktar, Ann C. Anselme, Laura C. Gomez, Wei Qian, Jianying Zhou, Kai Sun, Hong Zhao, et al.

    Obesity is associated with increased incidence and mortality in triple-negative breast cancer, however, the tumor-intrinsic mechanisms driving obesity-associated tumor progression remain poorly understood. Here, we identify the role of inducible nitric oxide synthase as a redox-active mediator that modulates obesity-associated inflammation and remodels the tumor microenvironment into an immunosuppressive state. iNOS expression was elevated in TNBC compared to other breast cancer subtypes and was associated with shorter overall survival, and obese TNBC patients preferentially benefited from iNOS inhibition combined with chemotherapy. In syngeneic TNBC models of diet-induced obesity, high-fat diet increased tumor growth and iNOS expression. Obesity-conditioned adipocytes induced tumor-cell iNOS expression and promoted iNOS-dependent production of the monocyte-recruiting chemokine CCL2. Tumor-specific deletion of iNOS abolished obesity-driven tumor progression and reprogrammed the tumor immune compartment by reducing recruitment of monocytic myeloid-derived suppressor cells, restoring antigen-presenting M1-like macrophages, and rescuing the tissue-resident memory-like cytotoxic T-cell population. Treatment with the pan-NOS inhibitor L-NMMA selectively enhanced the antitumor activity of docetaxel in obese, but not lean, tumor-bearing mice, and shifted the immune landscape of obese tumors toward that of lean controls. Together, these findings establish tumor-intrinsic iNOS as a key mediator of the obese tumor microenvironment through sustained nitric oxide signaling that promotes myeloid remodeling and impairs anti-tumor immunity. These results provide a strong rationale for clinical evaluation of iNOS-targeting strategies to enhance chemotherapy response, particularly in patients with obesity and TNBC.

  • Open Access

    Supplementary Table S1 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ann C. Anselme, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, et al.

    SUPPLEMENTARY Table 1: Stopping Rules

  • Open Access

    Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ann C. Anselme, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, et al.

    Supplementary Table 2: Representativeness of Study Participants

  • Open Access

    Data from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, Liliana Guzman, et al.

    Purpose:To evaluate the safety and efficacy of combining intratumoral IL12 gene therapy with docetaxel and pembrolizumab in high-risk patients with early-stage triple-negative breast cancer (TNBC) refractory to anthracycline-based neoadjuvant chemotherapy.Patients and Methods:In this single-arm, open-label phase II trial, patients with stages I to III TNBC and residual disease after anthracycline therapy received neoadjuvant docetaxel (100 mg/m2 i.v.) and pembrolizumab (200 mg i.v.) every 3 weeks for four cycles. Intratumoral injections of adenoviral-mediated interleukin 12 (ADV/IL12) gene therapy were administered 3 days prior to cycles 2 to 4. The primary endpoint was pathologic complete response (pCR). Secondary endpoints were safety and toxicity assessments. Correlative analyses included immune profiling and cytokine measurement.Results:Eight patients were enrolled; half received ADV/IL12 at a starting dose of 5 × 1011 viral particles (VP) in 2 mL volume, injected into the breast tumor. Owing to adverse events (AE), the remaining four patients received 3 × 1011 VPs. The trial was terminated early because of toxicity, with 87.5% of patients experiencing grade ≥3 AEs, including two treatment-related deaths. Only one (12.5%) patient who received a lower dose of ADV/IL12 achieved a pCR. Elevation of CCL4 levels was observed exclusively in the patient who achieved pCR.Conclusions:The combination of docetaxel, pembrolizumab, and intratumoral ADV/IL12 is associated with high systemic toxicity and minimal efficacy. These results underscore the need for cautious dose optimization and patient selection when integrating immunopotentiating cytokines into neoadjuvant regimens. Translational insights from this study inform safer design of future IL12-based strategies in immune-refractory TNBC.

  • Open Access

    Supplementary Table S1 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, Liliana Guzman, et al.

    SUPPLEMENTARY Table 1: Stopping Rules

  • Open Access

    Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, Liliana Guzman, et al.

    Supplementary Table 2: Representativeness of Study Participants

  • A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

    by Polly Niravath, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan, Mailin Li, Jenying Deng, Wei Qian, Jianying Zhou, Liliana Guzman, et al.

    Purpose: To evaluate the safety and efficacy of combining intratumoral IL12 gene therapy with docetaxel and pembrolizumab in high-risk patients with early-stage triple-negative breast cancer (TNBC) refractory to anthracycline-based neoadjuvant chemotherapy. Patients and Methods: In this single-arm, open-label phase II trial, patients with stages I to III TNBC and residual disease after anthracycline therapy received neoadjuvant docetaxel (100 mg/m2 i.v.) and pembrolizumab (200 mg i.v.) every 3 weeks for four cycles. Intratumoral injections of adenoviral-mediated interleukin 12 (ADV/IL12) gene therapy were administered 3 days prior to cycles 2 to 4. The primary endpoint was pathologic complete response (pCR). Secondary endpoints were safety and toxicity assessments. Correlative analyses included immune profiling and cytokine measurement. Results: Eight patients were enrolled; half received ADV/IL12 at a starting dose of 5 × 1011 viral particles (VP) in 2 mL volume, injected into the breast tumor. Owing to adverse events (AE), the remaining four patients received 3 × 1011 VPs. The trial was terminated early because of toxicity, with 87.5% of patients experiencing grade ≥3 AEs, including two treatment-related deaths. Only one (12.5%) patient who received a lower dose of ADV/IL12 achieved a pCR. Elevation of CCL4 levels was observed exclusively in the patient who achieved pCR. Conclusions: The combination of docetaxel, pembrolizumab, and intratumoral ADV/IL12 is associated with high systemic toxicity and minimal efficacy. These results underscore the need for cautious dose optimization and patient selection when integrating immunopotentiating cytokines into neoadjuvant regimens. Translational insights from this study inform safer design of future IL12-based strategies in immune-refractory TNBC.


  • Abstract 3991: NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer

    by Ivonne Uzair, Kai Sun, Ann Anselme, Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang

    Purpose of the study: To evaluate the role of obesity in tumor progression and tumor microenvironment (TME) dynamic after the inhibition of nitric oxide synthase (NOS) in syngeneic murine models engrafted with triple negative breast cancer (TNBC) tumors. For this study, we wanted to deepen the results of our recently completed phase I/II clinical trial, where treatment with NG-methyl-L-arginine (L-NMMA, a pan-NOS inhibitor) increased the response rate to chemotherapy (docetaxel) in obese metastatic TNBC (ER-/PR-/HER2-) patients to 86% vs. 60% in normal weight individuals. TME analysis from responders revealed a neutrophil phenotype shift from protumor N2 to antitumor N1. We thus hypothesize that combined treatment with L-NMMA and docetaxel enhances antitumor effect by modulating TME in obese mice with TNBC. Experimental procedures: 3-week old female C57BL/6 mice were fed for 10 weeks either with high fat diet (HFD) or normal diet (ND). At week 13, TNBC mouse E0771 tumor cells were injected into the mice mammary fat pad. Once tumors reached 100 mm3, the animals were randomized to four groups: vehicle; docetaxel; L-NMMA; and docetaxel plus L-NMMA treatment. Tumor volume was measured throughout the experiment and growth rate was compared between groups at the end of treatment. Blood, tumor and perigonadal white adipose tissue (pgWAT) were collected. Cytokines and nitrite/nitrate levels (NO2-/NO3-, a NO indicator) were measured from blood and conditioned media (CM) from pgWAT using appropriate kits. Tumor immune cell infiltration was evaluated by immunohistochemistry. GraphPad software was used for statistical analysis and P-values Citation Format: Ivonne Uzair, Kai Sun, Ann Anselme, Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang. NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3991.

  • Open Access

    Molecular Actions of Thyroid Hormone on Breast Cancer Cell Migration and Invasion via Cortactin/N-WASP

    by Ivonne Denise Uzair, Jeremias Conte Grand, Marina Ines Flamini, Angel Matias Sanchez

    The thyroid hormone triiodothyronine (T3) plays a fundamental role in growth regulation, differentiation, metabolism and cellular movement. These processes are particularly important considering that deregulation of T3 levels could promote abnormal responsiveness of mammary epithelial cells, which may lead to the development and progression of breast cancer (BC). Once cells migrate and invade different tissues, BC metastasis is the main cause of cancer-related death because it is particularly difficult to revert this multistep process. Cell migration integrates several steps that induce changes in cell structure and morphology to promote BC cell invasion. These sequential steps include actin cytoskeleton remodeling, focal adhesion complex formation and, finally, the turnover of branched actin filament networks. In this article, we demonstrate that T3 has the ability to modify the Epithelial-Mesenchymal Transition process. In addition, we show that T3 induces actin cytoskeleton reorganization, triggers focal adhesion formation and, as a consequence, promotes actin nucleation via non-genomic pathway. These events are specifically modulated by T3 via integrin αvβ3 to FAK/paxillin/cortactin/N-WASP/Arp2/3 complex signaling pathway, increasing cell adhesion, migration and invasion of T-47D BC cells. We suggest that T3 influences the progression of tumor metastasis by controlling signaling pathways that converge in cell motility. This knowledge is crucial for the development of novel therapeutic strategies for BC treatment.


  • Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases

    by Marina Inés Flamini, Ivonne Denise Uzair, Gisela Erika Pennacchio, Flavia Judith Neira, Joselina Magali Mondaca, Fernando Dario Cuello-Carrión, Graciela Alma Jahn, Tommaso Simoncini, Angel Matías Sanchez

    Thyroid hormones (TH) play a fundamental role in diverse processes, including cellular movement. Cell migration requires the integration of events that induce changes in cell structure towards the direction of migration. These actions are driven by actin remodeling and stabilized by the development of adhesion sites to extracellular matrix via transmembrane receptors linked to the actin cytoskeleton. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that promotes cell migration and invasion through the control of focal adhesion turnover. In this work, we demonstrate that the thyroid hormone triiodothyronine (T3) regulates actin remodeling and cell movement in breast cancer T-47D cells through the recruitment of FAK. T3 controls FAK phosphorylation and translocation at sites where focal adhesion complexes are assembled. This process is triggered via rapid signaling to integrin αV/β3, Src, phosphatidylinositol 3-OH kinase (PI3K), and FAK. In addition, we established a cellular model with different concentration of T3 levels: normal, absence, and excess in T-47D breast cancer cells. We found that the expression of Src, FAK, and PI3K remained at normal levels in the excess of T3 model, while it was significantly reduced in the absence model. In conclusion, these results suggest a novel role for T3 as an important modulator of cell migration, providing a starting point for the development of new therapeutic strategies for breast cancer treatment.